by Sarah Wesp | Apr 6, 2015
Pearl Pathways is excited to sponsor Q1 Productions’ and attend its upcoming IVD conference on Clinical Affairs and Regulatory Approvals for Diagnostics. The conference provides an excellent opportunity to network with industry experts and gain additional insight on...
by Sarah Wesp | Apr 6, 2015
FDA releases new guidance document in April 2015 regarding Critical Path Innovation Meetings (CPIM). The document strives to provide insight to pharmaceutical companies and the public regarding the acceleration of the drug development process through the Critical Path...
by Sarah Wesp | Apr 1, 2015
Please note that effective April 1, 2015, Pearl IRB has changed its fee schedule. See our 2015 Fee Schedule to view pricing for your upcoming study. For a price quote for Central IRB services, detailed pricing of your research project, or additional information about...
by Sarah Wesp | Mar 26, 2015
23andMe, a DNA analysis service company who provides information and tools to individuals to learn more about their DNA has announced its plan to invent its own drugs using customer data. This drastic move will allow 23andMe to capitalize on the economic value its...
by Sarah Wesp | Mar 26, 2015
To reduce the serious risk of spreading infections and ensure insulin pens and other injectable diabetes medicines are being used appropriately, FDA is mandating these injectable devices display the warning label “For single patient use only.” Multi-dose pen devices...
